Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05190471
Other study ID # BP1002-102-AML
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date August 16, 2022
Est. completion date September 2024

Study information

Verified date October 2022
Source Bio-Path Holdings, Inc.
Contact Michael Hickey
Phone 832-742-1361
Email mhickey@biopathholdings.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase) followed by assessing BP1002 in combination with decitabine (dose expansion phase).


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date September 2024
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adults =18 years of age, with histologic evidence of refractory/relapsed AML who have failed treatment with available therapies known to be active for refractory/relapsed AML 2. Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0, 1 or 2 3. For the dose expansion phase, participants with documented diagnosis of AML who are eligible for decitabine therapy 4. Participants must have adequate hepatic and renal functions as defined by: 1. Aspartate transaminase (AST) and alanine transaminase (ALT) =2.5 times the upper limit of normal (ULN); and 2. Usually total bilirubin = 1.5 ULN. In specific cases the PI may request a waiver of this requirement with medical justification and agreement with the medical monitor and Bio-Path Holdings. And; 3. Estimated creatinine clearance of at least 60 mL/min. These estimations are calculated using the Cockcroft-Gault equation. 5. Female participants of childbearing potential must agree to use an acceptable method of birth control (i.e. a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) for the duration of the study and for at least 6 months after the last dose of study drug or decitabine 6. Male participants must agree to use an acceptable method of contraception for the duration of the study 7. Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment 8. Participants must be willing and able to provide written informed consent Exclusion Criteria: 1. Active non-hematologic or lymphoid malignancy other than AML treated with immunotherapy, targeted therapy or chemotherapy within the previous 12 months 2. Known, active leptomeningeal leukemia requiring intrathecal therapy. NOTE: Participants with a history of CNS disease may be allowed to participate based on at least 1 documented, negative spinal fluid assessment within 28 days prior to Screening 3. Isolated potentially treatable extramedullary leukemia without also meeting bone marrow criteria for acute leukemia (for AML usually = 5% blasts in BMA or biopsy). Participants may have leukemia with lower blast counts (Döhner 2017). Bio-Path Holdings and Investigator concurrence required. 4. Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) PML-RARA 5. Chronic myeloid leukemia in any phase 6. Receipt of any anti-cancer therapy within 14 days prior to C1D1, with the exception of hydroxyurea or leukapheresis 7. Participants may not be receiving any other investigational agents 8. Female participants who are pregnant or breast-feeding 9. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results 10. Participants with human immunodeficiency virus (HIV) infection who have CD4+ T-cell counts < 350 cells/mcL or with clinically active hepatitis B or C infection 11. History of any hypersensitivity to hypomethylating agents, unless reaction is deemed irrelevant to the study by the Investigator and Medical Monitor 12. Unresolved toxicity higher than CTCAE Grade 1 attributed to any prior therapy or procedure, excluding alopecia 13. Presence of concurrent conditions that, in the opinion of the Investigator and/or Medical Monitor, may compromise the participant's ability to tolerate study treatment or interfere with any aspect of study conduct or interpretation of results. This includes, but is not limited to, unstable or uncontrolled angina, New York Heart Association (NYHA) class III or IV congestive heart failure, uncontrolled and sustained hypertension, clinically significant cardiac dysrhythmia or clinically significant baseline ECG abnormality (e.g., QTcF >470 msec) 14. Within the past 6 months, has had any of the following: myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack 15. Uncontrolled seizure disorder (i.e., seizures within the past 2 months) 16. Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
Dose escalation of BP1002 monotherapy
Decitabine (in combination with BP1002)
Dose expansion of BP1002 in combination with decitabine

Locations

Country Name City State
United States MD Anderson Cancer Center Houston Texas
United States Scripps Green Hospital La Jolla California
United States UCLA Medical Center Los Angeles California
United States Weill Cornell Medical College - NewYork-Presbyterian Hospital New York New York

Sponsors (1)

Lead Sponsor Collaborator
Bio-Path Holdings, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory objective to correlate treatment response with cytogenetic characteristics Flow cytometry assays to determine the effects of BP1002 on Bcl-2 protein expression 30 days
Other Exploratory objective to correlate treatment response with molecular characteristics Flow cytometry assays to determine the effects of BP1002 on Bcl-2 protein expression 30 days
Primary Identify Dose Limiting Toxicity (DLT) of BP1002 Identify DLT of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria 30 days
Primary Identify and grade treatment-emergent adverse events (TEAE) of escalating doses of BP1002 Identify TEAE of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria 30 days
Primary Identify and grade treatment-emergent laboratory abnormalities of escalating doses of BP1002 Identify and grade treatment-emergent laboratory abnormalities of escalating doses of BP1002 using non-hematologic and hematologic measure per NCI CTCAE criteria 30 days
Primary Recommended Phase 2 (RP2D) of BP1002 Determine RP2D by evaluating Maximally Tolerated Dose (MTD) data 210 days
Primary Determine plasma pharmacokinetics (PK) of BP1002 using maximum plasma drug concentration Evaluate plasma PK of BP1002 using maximum plasma drug concentration (Cmax) 30 days
Primary Determine plasma pharmacokinetics (PK) of BP1002 using volume of distribution Evaluate in vivo PK of BP1002 using volume of distribution (Vd) 30 days
Primary Determine plasma pharmacokinetics (PK) of BP1002 using elimination rate constant Evaluate in vivo PK of BP1002 using elimination rate constant 30 days
Primary Determine half-life plasma pharmacokinetics (PK) of BP1002 Evaluate in vivo PK of BP1002 half-life (t1/2) 30 days
Primary Identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in ECG intervals) of escalating doses of BP1002 Collection of 12-lead ECGs at defined intervals to identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in ECG intervals) 30 days
Primary Determine pharmacodynamics (PD) of BP1002 Flow cytometry will be performed using peripheral blood to evaluate Bcl-2 target inhibition by BP1002 on pre and post treatment samples 30 days
Primary Determine anti-drug antibody (ADA) levels of BP1002 Evaluate ADA via peripheral blood 30 days
Secondary Determine evidence of response by bone marrow aspirate Assess complete remission (CR), CR with incomplete hematologic recovery (CRi), and CR with partial hematologic recovery (CRh) per Döhner 2017 180 days
Secondary Determine evidence of response by complete blood counts using peripheral blood Assess complete remission (CR), CR with incomplete hematologic recovery (CRi), and CR with partial hematologic recovery (CRh) per Döhner 2017 180 days
Secondary Assessment of morphologic leukemia free state (MLFS) and partial remissions by bone marrow aspirate and complete blood counts To assess percentage of participants with MLFS and partial remissions per Döhner 2017 180 days
Secondary Assessment of morphologic leukemia free state (MLFS) and partial remissions by bone marrow aspirate To assess percentage of participants with MLFS and partial remissions per Döhner 2017 180 days
Secondary Assessment of blast count reductions by complete blood counts using peripheral blood To assess blast count reductions per Williams 2016 180 days
Secondary To determine progression-free survival (PFS), overall survival (OS), and duration of response To assess progression-free survival (PFS), overall survival (OS), and duration of response from date of study entry to study closure or death 180 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02204085 - A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT06125652 - Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) Phase 1/Phase 2
Recruiting NCT05105152 - PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML Phase 1
Recruiting NCT05597306 - Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT04898894 - Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Phase 1
Recruiting NCT05546580 - Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) Phase 1
Recruiting NCT03957915 - Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia Early Phase 1
Recruiting NCT05317403 - Venetoclax to Augment Epigenetic Modification and Chemotherapy Phase 1
Recruiting NCT04867928 - Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia Phase 2
Completed NCT04402541 - Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Not yet recruiting NCT04716452 - Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05211570 - AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Terminated NCT03690154 - A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML Phase 1
Recruiting NCT05735184 - A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML Phase 1
Recruiting NCT05124288 - Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
Recruiting NCT05506332 - Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05949125 - Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 Phase 1
Recruiting NCT06128044 - CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Completed NCT04321161 - Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment Early Phase 1
Not yet recruiting NCT06281847 - An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia Phase 1/Phase 2